Patent applications published 4 August 2010
Selected patent applications from the weekly European Patents Bulletin
- Pyridosulphonamide derivatives as P13 kinase inhibitors
GlaxoSmithKline 2211615*
- Method of making imidazoazepinone compounds
Eisai R&D_Management 2211616*
- Concentrated aqueous azalide formulations
Insite Vision 2211617*
- Piperidinylhydroxyethylpiperidines as modulators of chemokine receptors
Glaxo Group 2211618*
- Substituted 1,2,4-oxadiazoles and analogues thereof as CB2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases
Merck Sharp &_Dohme 2211619*
- Therapeutic compounds
Merck Sharp &_Dohme 2211620*
- Method for preparing a vaccine compsn comprising at least one antigen and at least one adjuvant
Societe d’Exploitation de Produits Pour Les Industries Chimiques Seppic 2211834*
- Topical ophthalmic or otic colution formulations containing moxifloxacin hydrochloride and dexamethasone phosphate
Alcon Research 2211835*
- Taste masked orally disintegrating tablets of memantine hydrochloride
Rubison Research Private 2211836*
- A non-aqueous topical solution of diclofenac and process for preparing the same
Troikaa Pharmaceuticals 2211837*
- Bowel purgative and uses thereof
Thomas Jefferson University 2211838*
- Long acting injectable formulations
Intervet International 2211839*
- Amphoteric liposomes comprising neutral lipids
Novosum 2211840*
- Method of prophylaxis and agents for use therein
Cooperative Research Centre for Asthma 2211841*
- Method of preventing adverse effects by GLP-1
Mannkind 2211842*
- Pharmaceutical moire pill
I-Property Holding Corp 2211843*
- Film delivery system incorporating small scale actives
MonoSol RX 2211844*
- Glucocorticoid receptor antagonists such as mefipristone for treating Cushing’s syndrome
Laboratoire HRA_Pharma 2211845*
- New therapeutic approaches for treating CMT_and related disorders
Pharnext 2211846*
- Controlled-release pharma formulation
Alphapharm 2211847*
- Trans-clomiphene for metabolic syndrome
Repros Therapeutics 2211848*
- Dexanabinol with inhibitors of BRAF_or MEK_for the treatment of melanoma
E-Therapeutics 2211849*
- A system and method to improve memory function
Handevelop 2211850*
- Laminins, derivatives and compsns including same, and method for their therapeutic use
Board of Regents of the Nevada System of Higher Education, on behalf of the University of Nevada 2211851*
- Compsns and methods for reducing hepatotoxicity associated with drug adminstration
Yale University 2211852*
- A cancer sensitiser comprising chlorogenic acid
National Cancer Centre 2211853*
- Methods and compsns for th treatment of cancer using benzopyrone-type PARP inhibitors
BiPar Sciences 2211854*
- Thrombopoietin receptor agonist (TPORA) kills acute human myeloid leukaemia cells
The Trustees of the University of Pennsylvania 2211855*
- Compsns and methods for treating lysosomal disorders
The Hospital for Sick Children, Neuraltus Pharmaceuticals 2211856*
- Use of quaternary pyridinium salts for radioprotection
Politechnika Lodzka 2211857*
- Use of pyridonium salts for inhibiting cancer metastases
Politechnika Lodzka 2211858*
- Metabotropic glutamate receptor modulators for the treatment of Parkinson’s disease
Novartis 2211859*
- Combination therapy for reducing side effects using cannabinoid receptor ligands
Abbott Laboratories 2211860*
- Clioquinol for the treatment of haemato-logical malignancies
University Health Network 2211861*
- CSF-1R inhibitors for treatment of cancer and bone diseases
Novartis 2211862*
- Combination therapy
Merck Frosst Canada 2211863*
- Pyrazinyl amide T-type calcium channel antagonists
Merck Sharpe &_Dohme 2211864*
- Combination comprising purine derivatives and other compounds and the use thereof for the treatment of inflammatory and obstructive airway diseases
Novartis 2211865*
- Antiemetic-oral contraceptive combination
Lupin 2211866*
- Process for synthesising phosphonic and phosphinic acid compounds
Janssen Pharmaceutica 2211867*
- Silicate containing compsns and methods of treatment
7 Oaks Pharmaceutical Corp 2211868*
- Cytidine analogues for treatment of myelodysplastic syndromes
Celgene 2211870*
- Method for inhibiting angiogenesis or for treatment of cancer
Faron Ventures 2211871*
- Hyperbranched polyglycerol for improving heart function
The University of British Columbia 2211872*
- Stable amorphous calcium carbonate comprising phosphorylated amino acids, synthetic phosphorylated peptides, and gastrolith proteins
Amorphical 2211873*